a clinical and metabolic study of 32 patients treated with glibenclamide for a period of about one year confirmed that the drug is a potent stimulator of insulin release in maturity onset diabetes , and glibenclamide continued to have this action after a period of eight months .
C0021641
insulin
C0011860
maturity onset diabetes